Drug Profile
sEphB4-HSA - VasGene Therapeutics
Alternative Names: EphB4-HSA; EphB4-Human Serum Albumin; Human Serum Albumin-EphB4 conjugate; Recombinant EphB4-HSA Fusion Protein; Vas 01Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator VasGene Therapeutics
- Developer National Cancer Institute (USA); University of Southern California; VasGene Therapeutics
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action EphB4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Bladder cancer; Chronic myelomonocytic leukaemia; Head and neck cancer; Kaposi's sarcoma; Myelodysplastic syndromes; Non-small cell lung cancer; Prostate cancer; Solid tumours; Urogenital cancer
- No development reported Leukaemia; Renal cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV)
- 25 Oct 2022 Vasgene Therapeutics and University of Colorado completes a phase-I clinical trial in Head and neck cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT04091867)
- 19 Aug 2022 Vasgene Therapeutics terminates phase I trial in Solid tumours (metastatic or recurrent disease) in USA (IV) due to lack of funding (NCT01642342)